antithrombotics trial summary

Trial	Studied treatment	Control treatment	patients	ROB	Result	NCT
acute coronary syndrome
apixaban
APPRAISE-1 (10mg od), 2009	apixaban	placebo		Exploratory	Negative	NCT00313300
APPRAISE-1 (2.5 mg bid), 2009	apixaban	placebo			Negative	NCT00313300
APPRAISE 2, 2011	apixaban	placebo		Low risk of bias	Negative	NCT00831441
APPRAISE japan ongoing	apixaban	placebo		Exploratory	-	NCT00852397
argatroban
ARGAMI-2, 1998	Argatroban	heparin			-
aspirin
VA-pilot	aspirin	placebo			Negative
ALDUSA-pilot	aspirin	placebo			Negative
VA-main, 1983	aspirin	placebo			Suggesting
Canadian (Aspirin + sulfinpyrazone), 1985	aspirin + sulfinpyrazone	placebo			Negative
Canadian (Aspirin vs PBO), 1985	aspirin	placebo			-
Théroux, 1988	aspirin	placebo			Suggesting
RISC, 1990	aspirin	placebo			Suggesting
ATACS-pilot, 1990	aspirin	control			Negative
atopaxar
LANCELOT ACS	atopaxar	placebo		Exploratory	-
J-LANCELOT, 2010	atopaxar	placebo		Exploratory	-
bivalirudin
BAT (Bittl), 1995	bivalirudin	heparin		Low risk of bias	Suggesting
HERO, 1997	bivalirudin	heparin		Exploratory	Suggesting
PROTECT-TIMI 30, 2006	bivalirudin	eptifibatide + heparin		Exploratory	-	NCT00250471
ACUITY (biva alone vs hep+aGP2b3a), 2006	bivalirudin	heparin + GP2b3a inhibitors			Suggesting	NCT00093158
ACUITY (biva+aGP2b3a vs hep+aGP2b3a), 2006	bivalirudin + GP2b3a inhibitors	heparin + GP2b3a inhibitors			Negative	NCT00093158
ACUITY (sub groups PCI, bivalirudin +aGP2b3a) importé, 2007	bivalirudin + GP2b3a inhibitors	heparin + GP2b3a inhibitors			Negative
ACUITY (sub groups PCI, bivalirudin alone) importé, 2007	bivalirudin	heparin + GP2b3a inhibitors			Suggesting
clopidogrel
CURE, 2001	clopidogrel + aspirin	aspirin			Suggesting
CURE (PCI sub study), 2001	clopidogrel	placebo		Exploratory	-
CURRENT OASIS 7 (clopidogrel), 2010	clopidogrel high-dose regimen	clopidogrel standard-dose		Low risk of bias	Negative	NCT00335452
coumadin
ASPECT-2 (coumadin+asp vs asp), 2002	coumadin	control (on top of aspirin)			Suggesting
ASPECT-2 (coumadin vs aspirin), 2002	coumadin	aspirin			Suggesting
dalteparin
FRISC (long term), 1996	dalteparin	placebo (on top of aspirin)		Exploratory	Suggesting
FRISC (short term), 1996	dalteparin	placebo (on top of aspirin)		Low risk of bias	-
FRIC (acute phase LMWH vs UFH), 1997	dalteparin	UFH (on top of aspirin)		Exploratory	Negative
FRIC prolonged treatment phase (LWMH vs PBO), 1997	dalteparin	placebo (on top of aspirin)			Negative
dipyridamol
Prandoni, 1991	aspirin + dipyridamol	placebo			Negative
Efegatran
Klootwijk, 1999	Efegatran	heparin		Exploratory	-
enoxaparin
RESCUE	enoxaparin	unfractionated heparin			-	NCT00077818
ESSENCE, 1997	enoxaparin	UFH (on top of aspirin)			Suggesting
TIMI 11 B (short term), 1998	enoxaparin	UFH (on top of aspirin)			Suggesting
TIMI 11 B (long term), 1998	enoxaparin	UFH (on top of aspirin)			Negative
SYNERGY, 2005	enoxaparin	UFH (on top of aspirin)			Negative	NCT00043784
EVET, 2005	enoxaparin	tinzaparin			Suggesting
INTERACT, 2006	enoxaparin	UFH (on top of aspirin)			Suggesting
fondaparinux
PENTUA, 2004	fondaparinux	enoxaparin			-
OASIS 5, 2006	fondaparinux	enoxaparin			-	NCT00139815
hirudin
HELVETICA (Serruys), 1995	Hirudin	heparin		Low risk of bias	-
TIMI 9B, 1996	Hirudin	heparin		Risk of bias	-
GUSTO IIB, 1996	Hirudin	heparin		Risk of bias	-
OASIS pilot, 1997	Hirudin	heparin		Exploratory	-
OASIS, 1997	Hirudin	heparin		Risk of bias	-
HIT-4, 1999	Hirudin	heparin		Exploratory	-
OASIS 2, 1999	Hirudin	heparin		Low risk of bias	-
inogatran
TRIM, 1997	Inogatran	heparin		Exploratory	-
nadroparin
FRAXIS (6days), 1998	nadroparin	UFH (on top of aspirin)		Low risk of bias	Negative
FRAXIS (14 days), 1998	nadroparin	UFH (on top of aspirin)			Negative
otamixaban
SEPIA-ACS1 TIMI 42, 2009	otamixaban	unfractionated heparin		Exploratory	Suggesting	NCT00317395
prasugrel
TRITON-TIMI 38, 2007	prasugrel	clopidogrel		Low risk of bias	Suggesting	NCT00097591
TRILOGY ACS (overall population), 2012	prasugrel	clopidogrel		Low risk of bias	Negative	NCT00699998
ACAPULCO ongoing	prasugrel	clopidogrel			-
rivaroxaban
ATLAS ACS 2 - TIMI 51 (2.5mg), 2011	rivaroxaban 2.5mg	placebo		Low risk of bias	Suggesting	NCT00809965
ATLAS ACS 2 - TIMI 51 (5mg), 2011	rivaroxaban 5mg	placebo			Suggesting	NCT00809965
sulfinpyrazone
Canadian (sulfinpyrazone alone), 1985	sulfinpyrazone	placebo			-
ticagrelor
DISPERSE-2 (90mg), 2007	ticagrelor	clopidogrel		Exploratory	Negative
PLATO, 2009	ticagrelor	clopidogrel		Low risk of bias	Suggesting	NCT00391872
ticlopidine
Florida UA	ticlopidine	placebo			Negative
STAI, 1990	ticlopidine	control			Suggesting
trapidil
Modena	trapidil	placebo			Suggesting
triflusal
Plaza, 1993	triflusal	placebo			Suggesting
TIM, 2000	triflusal	aspirin			-
UFH
Theroux (heparin+aspirin vs PBO), 1988	UFH + aspirin	placebo			Suggesting
Theroux (heparin vs PBO), 1988	UFH	placebo			Suggesting
Theroux (heparin+ASP vs ASP), 1988	UFH	control (on top of aspirin)			Suggesting
Cohen (ATACS pilot) (heparin+aspirin vs asp), 1990	UFH, warfarin	control (on top of aspirin)			Negative
RISC (heparin+aspirin vs ASP), 1990	UFH	control (on top of aspirin)			Negative
RISC (heparin vs PBO), 1990	UFH	placebo			Negative
Cohen (ATACS pilot) (heparin vs asp), 1990	UFH, warfarin	aspirin			Negative
RISC (ASP+ heparin vs PBO), 1990	UFH + aspirin	placebo			Suggesting
ATACS (Cohen), 1994	UFH, warfarin	control (on top of aspirin)			Negative
Holdright, 1994	UFH	control (on top of aspirin)			Negative
Gurfinkel (UFH+aspririn vs aspirin), 1995	UFH	placebo (on top of aspirin)			Negative
vorapaxar
TRACER, 2011	vorapaxar	placebo (on top standard therapy)		Low risk of bias	-	NCT00527943
warfarin
ATACS (pilot study) (warfarin vs control), 1990	warfarin	control (on top of aspirin)			Negative
ATACS (pilot study) warfarin vs aspirin, 1990	warfarin	aspirin			Negative
ATACS, 1994	warfarin	control (on top of aspirin)			Negative
Williams, 1997	warfarin	placebo (on top of aspirin)			Negative
CARS, 1997	warfarin	control (on top of aspirin)			Negative
OASIS Pilot (phase 1), 1998	warfarin	control (on top of aspirin)			Negative
OASIS Pilot (phase 2), 1998	warfarin	control (on top of aspirin)			Negative
Huyhn, 2001	warfarin	placebo (on top of aspirin)			Negative
OASIS-2 Warfarin Substudy, 2001	warfarin	control (on top of aspirin)			Negative
APRICOT-2, 2002	warfarin	control (on top of aspirin)			Negative
CHAMP, 2002	warfarin	control (on top of aspirin)			Negative
WARIS, 2002	warfarin	control (on top of aspirin)			Suggesting
LoWASA, 2004	warfarin	control (on top of aspirin)			Negative
Zibaeenezhad, 2004	warfarin	control (on top of aspirin)			Negative
ximelagatran
ESTEEM, 2003	ximelagatran	placebo		Exploratory	-
acute myocardial infarction
argatroban
ARGAMI-2, 1998	Argatroban	heparin			-
bivalirudin
HERO, 1997	bivalirudin	heparin		Exploratory	Suggesting
coumadin
ASPECT, 1994	coumadin	placebo			Suggesting
ASPECT-2 (coumadin alone), 2002	coumadin	aspirin			Suggesting
ASPECT-2 (coumadin+ASA vs ASA), 2002	coumadin	control (on top of aspirin)			Negative
dalteparin
FRAMI, 1997	Dalteparin	placebo			-
BIOMACS II, 1999	Dalteparin	placebo			-
ASSENT Plus, 2003	Dalteparin	UFH			Negative
enoxaparin
ASSENT 3, 2001	Enoxaparin	UFH			Suggesting
HART II, 2001	Enoxaparin	UFH			Negative
Baird, 2002	Enoxaparin	UFH			Negative
ENTIRE-TIMI 2, 2002	Enoxaparin	UFH			Suggesting
AMI-SK, 2002	Enoxaparin	placebo			-
ASSENT 3 Plus, 2003	Enoxaparin	UFH			Negative
fondaparinux
MICHELANGELO OASIS-6, 2006	fondaparinux	placebo		Low risk of bias	Suggesting	NCT00064428
hirudin
TIMI 9B, 1996	Hirudin	heparin		Risk of bias	-
HIT-4, 1999	Hirudin	heparin		Exploratory	-
reviparin
CREATE, 2005	Reviparin	placebo			-
UFH
ISIS-2 Pilot, 1987	UFH	no heparin			Negative
ECSG, 1992	UFH	placebo			Negative
OSIRIS, 1992	UFH	placebo			Negative
DUCCS, 1994	UFH	no heparin			Negative
warfarin
Williams, 1997	warfarin	placebo (on top of aspirin)			Suggesting
CARS (warafrin 3mg), 1997	warfarin	control (on top of aspirin)			Suggesting
CARS (warfarin 1mg), 1997	warfarin	control (on top of aspirin)			Negative
WARIS, 1999	warfarin	control (on top of aspirin)			-
APRICOT-2, 2002	warfarin	control (on top of aspirin)			Suggesting
WARIS II (warfarin alone), 2002	warfarin	aspirin			Suggesting
CHAMP, 2002	warfarin	control (on top of aspirin)			Negative
WARIS II (warfarin+ASA), 2002	warfarin	control (on top of aspirin)			Suggesting
Zibaeenezhad, 2004	warfarin	control (on top of aspirin)			Negative
LoWASA, 2004	warfarin	control (on top of aspirin)		Risk of bias	Suggesting
atrial fibrillation
apixaban
phase 2 apixaban	apixaban	warfarin standard dose		Exploratory	-	NCT00787150
ARISTOTLE, 2011	apixaban	warfarin standard dose		Low risk of bias	Conclusive	NCT00412984
AVERROES, 2011	apixaban	aspirin	ineligible for VKA	Low risk of bias	Suggesting	NCT00496769
aspirin
AFASAK (aspirin vs placebo), 1989	aspirin	placebo		Low risk of bias	Negative
AFASAK (aspirin vs warfarin standard dose), 1989	aspirin	warfarin standard dose		Risk of bias	Negative
SPAF (aspirin,warfarin ineligible arm), 1991	aspirin	placebo	ineligible for VKA	Low risk of bias	Negative
SPAF (aspirin , warfarin eligible arm), 1991	aspirin	placebo		Low risk of bias	Suggesting
EAFT, 1993	aspirin	placebo			Negative
SPAF II (aspirin vs warfarin standard dose, age<75), 1994	aspirin	warfarin standard dose		Risk of bias	Negative
SPAF II (aspirin vs warfarin standard dose, age>75), 1994	aspirin	warfarin standard dose		Risk of bias	Negative
AFASAK II (aspirin vs warfarin low dose), 1998	aspirin	warfarin low dose		Risk of bias	Negative
AFASAK II (aspirin vs warfarin standard dose), 1998	aspirin	warfarin standard dose		Risk of bias	Negative
PATAF (vs coumadin low dose), 1999	aspirin	coumadin low dose		Risk of bias	Negative
PATAF (vs coumadin standard dose), 1999	aspirin	coumadin standard dose		Risk of bias	Negative
LASAF(aspirin vs no treatment), 1999	aspirin	control			-
FFAACS , 2001	aspirin	placebo (on top fluidione)			Negative
BAFTA (aspirin vs warfarin standard dose) ongoing	aspirin	warfarin standard dose			-
clopidogrel
ACTIVE W, 2006	aspirin + clopidogrel	anticoagulant		Risk of bias	Suggesting	NCT00243178
ACTIVE A, 2009	aspirin + clopidogrel	aspirin		Low risk of bias	Suggesting	NCT00249873
coumadin
PATAF (coumadin low dose vs coumadin standard dose), 1999	coumadin low dose	coumadin standard dose		Risk of bias	Negative
dabigatran
RE-LY 150mg (2nd prevention subgroup)	dabigatran 150mg	warfarin		Exploratory	Suggesting
phase 2 dabigatran	dabigatran	warfarin standard dose		Exploratory	-	NCT01136408
PETRO (150mg), 2007	dabigatran 150mg	warfarin standard dose		Exploratory	-
RE-LY (150mg), 2009	dabigatran 150mg	warfarin standard dose		Risk of bias	Suggesting	NCT00262600
RE-LY (110mg), 2009	dabigatran 110mg	warfarin standard dose		Risk of bias	Suggesting	NCT00262600
RE-LY 110mg (2nd prevention subgroup) , 2010	dabigatran 100mg	warfarin		Exploratory	Suggesting
edoxaban
Weitz (edoxaban phase 2)	edoxaban	warfarin standard dose		Exploratory	-	NCT00504556
phase 2 edoxaban	edoxaban	warfarin standard dose		Exploratory	-	NCT00806624
ENGAGE-AF TIMI 48 High dose, 2013	edoxaban high dose	warfarin standard dose		Low risk of bias	Suggesting	NCT00781391
idraparinux
AMADEUS, 2008	idraparinux	warfarin standard dose		Risk of bias	Negative	NCT00070655
idraparinux BOREALIS-AF ongoing	idraparinux	warfarin standard dose			-	NCT00580216
rivaroxaban
ROCKET-AF, 2010	rivaroxaban	warfarin standard dose		Low risk of bias	Suggesting	NCT00403767
ROCKET (2nd prevention subgroup) , 2011	rivaroxaban	warfarin			Negative
ROCKET J ongoing	rivaroxaban	warfarin standard dose			-	NCT00494871
triflusal
NASPEAF (triflusal vs coumadin standard dose)), 2004	triflusal	coumadin standard dose		Risk of bias	Negative
warfarin
AFASAK (warfarin standard dose vs control), 1989	warfarin standard dose	control		Risk of bias	Suggesting
BAATAF (warfarin vs no treatment), 1990	warfarin low dose	control		Risk of bias	Suggesting	NCT00000517
CAFA, 1991	warfarin standard dose	placebo		Low risk of bias	Negative
SPAF (warfarin standard dose), 1991	warfarin standard dose	control		Risk of bias	Suggesting
SPINAF (warfarin vs placebo), 1992	warfarin low dose	placebo		Low risk of bias	Negative
SPAF III, 1996	warfarin + aspirin	warfarin standard dose		Risk of bias	-
AFASAK II (warfarin low dose vs warfarin standard dose), 1998	warfarin low dose	warfarin standard dose		Risk of bias	Negative
AFASAK II (warfarin low dose+aspirin vs warfarin standard dose), 1998	warfarin + aspirin	warfarin standard dose		Risk of bias	Negative
MWNAF, 1998	warfarin low dose	warfarin standard dose		Risk of bias	Negative
SAFT(warfarin low dose + aspirin vs no treatment), 2003	warfarin low dose + aspirin	control		Risk of bias	Negative
ximelagatran
SPORTIF II (ximelagatran vs warfarin standard dose), 2002	ximelagatran	warfarin standard dose		Risk of bias	-
SPORTIF III, 2003	ximelagatran	warfarin standard dose		Risk of bias	Suggesting
SPORTIF V, 2005	ximelagatran	warfarin standard dose		Low risk of bias	Suggesting
heart failure
aspirin
Barzizza (ASA), 1993	aspirin	placebo		Exploratory	-
WASH (aspirin), 2004	aspirin	no treatment			Negative
clopidogrel
WATCH (clopidogrel vs aspirin) ongoing	clopidogrel	aspirin			-
enoxaparin
THE-PRINCE (Kleber), 2003	enoxaparin	UFH			-
rivaroxaban
COMMANDER HF, 2018	rivaroxaban	placebo			Negative	NCT01877915
warfarin
Barzizza (warfarin), 1993	warfarin	placebo			-
WASH (warfarin), 2004	warfarin	no treatment			Negative
HELAS (warfarin vs aspirin), 2006	warfarin	aspirin			-
HELAS (warfarin vs placebo), 2006	warfarin	placebo			-
WATCH (warfarin vs aspirin), 2009	warfarin	aspirin			Suggesting	NCT00007683
percutaneous coronary intervention
abciximab
EPIC (with infusion), 1994	Abciximab	placebo			-
Simoons, 1994	Abciximab	placebo			-
EPILOG, 1997	Abciximab	placebo			-
CAPTURE, 1997	Abciximab	placebo			-
RAPPORT, 1998	Abciximab	placebo			-
EPISTENT, 1998	Abciximab	placebo			-
ERASER, 1999	Abciximab	placebo			-
ISAR-2, 2000	Abciximab	placebo			-
ADMIRAL, 2001	Abciximab	placebo			-
Kini, 2001	Abciximab	placebo			-
CADILLAC, 2002	Abciximab	placebo			-
Petronio, 2002	Abciximab	placebo			-
Tamburino, 2002	Abciximab	placebo			-
aspirin
Taylor (Perth), 1991	aspirin	placebo			Negative
M-HEART II (aspirin), 1995	aspirin	placebo			Negative
bivalirudin
ARMYDA BIVALVE	bivalirudin	UFH			-
BAT (Bittl), 1995	bivalirudin	UFH		Low risk of bias	Suggesting
Kleiman, 2002	bivalirudin + eptifibatide	heparin + GP2b3a inhibitors		Exploratory	-
REPLACE-2, 2003	bivalirudin	heparin + GP2b3a inhibitors			-
REPLACE-1, 2004	bivalirudin	UFH		Exploratory	Negative
ACUITY (Stone) (bivalirudin alone), 2006	bivalirudin	heparin + GP2b3a inhibitors		Risk of bias	-	NCT00093158
ISAR-REACT 3, 2008	bivalirudin	UFH		Low risk of bias	-	NCT00262054
HORIZONS-AMI (Stone), 2008	bivalirudin	heparin + GP2b3a inhibitors		Risk of bias	Suggesting	NCT00433966
NAPLES (Tavano), 2009	bivalirudin	UFH plus tirofiban		Risk of bias	Suggesting
BRAVE-4 ongoing	Prasugrel and Bivalirudin	Clopidogrel and Heparin			-	NCT00976092
cangrelor
CHAMPION-PLATFORM, 2009	cangrelor up front	delayed clopidogrel			Negative	NCT00385138
CHAMPION-PCI, 2009	cangrelor up front	clopidogrel up front		Low risk of bias	Negative	NCT00305162
CHAMPION PHOENIX, 2013	cangrelor	clopidogrel		Low risk of bias	Suggesting	NCT01156571
cilostazol
Kunishima, 1997	cilostazol	aspirin			Negative
Sekiya, 1998	cilostazol + aspirin	aspirin			Negative
Ochiai, 1999	cilostazol + aspirin	ticlopidine + aspirin			Negative
Park, 1999	cilostazol + aspirin	ticlopidine + aspirin			Negative
Yoon, 1999	cilostazol + aspirin	ticlopidine + aspirin			Negative
Kozuma, 2001	cilostazol + aspirin	ticlopidine + aspirin			Negative
Kamishirado, 2002	cilostazol + aspirin	ticlopidine + aspirin			Negative
clopidogrel
Müller, 2000	clopidogrel + aspirin	ticlopidine + aspirin			Negative
CLASSICS, 2000	clopidogrel + aspirin	ticlopidine + aspirin			Negative
TOPPS, 2001	clopidogrel + aspirin	ticlopidine + aspirin			Negative
Piamsomboon, 2001	clopidogrel + aspirin	ticlopidine + aspirin			Negative
GRAVITAS, 2011	high-dose clopidogrel	normal-dose clopidogrel		Risk of bias	Negative	NCT00645918
dalteparin
Natarajan (without antiGp2b3a), 2003	dalteparin	UFH			-
Natarajan (+ antiGp2b3a), 2003	dalteparin	UFH + anti Gp2b3a			-
dipyridamol
Schwartz (Toronto), 1988	aspirin + dipyridamol	placebo			Suggesting
Mayo-PTCA, 1989	aspirin + dipyridamol	placebo			Negative
Nye (Dunedin), 1990	aspirin + dipyridamol	placebo			Negative
White (aspirin+dipiridamol), 1991	aspirin + dipyridamol	placebo			Negative
elinogrel
INNOVATE PCI	elinogrel	clopidogrel			-	NCT00751231
enoxaparin
Rabah, 1999	enoxaparin	UFH		Exploratory	Negative
Dudek, 2000	enoxaparin	UFH			Negative
Dudek b (enox alone), 2000	enoxaparin	UFH			-
Galeote, 2001	enoxaparin	UFH			Negative
Drozd, 2001	enoxaparin	UFH			Negative
Dubek b (+abciximal), 2001	enoxaparin+abciximab	UFH			-
CRUISE, 2003	enoxaparin	UFH		Exploratory	Negative
STEEPLE, 2006	enoxaparin	UFH		Risk of bias	-	NCT00077844
ATOLL, 2010	enoxaparin	UFH		Risk of bias	-
STREAM ongoing	enoxaparin	unfractionated heparin			-	NCT00882635
eptifibatide
IMPACT (4h), 1995	Eptifibatide	placebo			-
Harrington, 1995	Eptifibatide	placebo			-
IMPACT-II (0.5µg), 1997	Eptifibatide	placebo			-
ESPRIT, 2000	Eptifibatide	placebo			-
fondaparinux
SWITCH III ongoing	fondaparinux	unfractionated heparin or bivalirudin			-	NCT00464087
prasugrel
JUMBO-TIMI 26, 2005	prasugrel	clopidogrel		Exploratory	Negative
TRITOM TIMI 38 (PCI subgroup), 2009	prasugrel	clopidogrel			-
TRIGGER-PCI ongoing	prasugrel	Clopidogrel			-	NCT00910299
reviparin
REDUCE, 1996	reviparin	UFH		Low risk of bias	Suggesting
sulotroban
M-HEART II (sulotroban), 1995	sulotroban	placebo			-
ticlopidine
TACT, 1990	ticlopidine	placebo			Negative
White (ticlopidine), 1991	ticlopidine	placebo			-
ISAR, 1996	ticlopidine + aspirin	coumadin + aspirin			Suggesting
Hall, 1996	ticlopidine + aspirin	aspirin			Negative
FANTASTIC, 1998	ticlopidine + aspirin	coumadin + aspirin			Negative
MATTIS, 1998	ticlopidine + aspirin	coumadin + aspirin			Negative
STARS (vs coumadin+asp), 1998	ticlopidine + aspirin	coumadin + aspirin			Suggesting
STARS (vs aspirin), 1998	ticlopidine + aspirin	aspirin			Suggesting
Foussas, 2000	ticlopidine + aspirin	coumadin + aspirin			Suggesting
tirofiban
Kereiakis, 1996	Tirofiban	placebo			-
RESTORE, 1997	Tirofiban	placebo			-
peripheral vascular diseases
acenocoumarol
APIC, 1989	acenocoumarol	placebo			-
aspirin
Lassila R, 1991	aspirin	contrôle			-
BOA, 2000	aspirin				-
CLIPS, 2007	aspirin	placebo		Low risk of bias	Suggesting
clopidogrel
AFFIRM ongoing	clopidogrel				-
ticlopidine
Becquemin, 1997	ticlopidine	contrôle			-
UFH
Tesi, 1989	HNF	placebo			-
Antonicelli, 1999	HNF	placebo			-
warfarin
Sarac, 1998	warfarin	contrôle			-
Johnson, 2002	warfarin	contrôle			-
post acute coronary syndromes
dabigatran
REDEEM, 2009	dabigatran	placebo			Negative	NCT00621855
post myocardial infarction
dabigatran
REDEEM, 2009	dabigatran	placebo			Negative	NCT00621855
pulmonary embolism
apixaban
AMPLIFY-EXT 2.5mg, 2012	apixaban 2.5mg	discontinuation			Suggesting	NCT00633893
AMPLIFY-EXT 5mg, 2012	apixaban 5mg	discontinuation			Suggesting	NCT00633893
AMPLIFY, 2013	apixaban (without LMWH)	LMWH/VKA		Low risk of bias	Suggesting	NCT00643201
Certoparin
Certoparin-Study Group sub group, 1998	Certoparin	unfractionated heparin		Exploratory	Negative
dalteparin
Kuijer, 1995	Dalteparin	unfractionated heparin			Negative
Meyer, 1995	Dalteparin	unfractionated heparin			Negative
enoxaparin
PREPIC, 1998	Enoxaparin	unfractionated heparin		Risk of bias	Negative
Merli sub group, 2001	Enoxaparin	unfractionated heparin		Exploratory	Negative
fondaparinux
MATISSE PE, 2003	fondaparinux	heparin		Risk of bias	Negative
idraparinux
VanGogh PE, 2007	idraparinux (without heparin)	heparin/VKA		Risk of bias	Negative	NCT00062803
nadroparin
European multicentre study, 1991	Nadroparin	unfractionated heparin		Risk of bias	Negative
Prandoni sub-group, 1992	Nadroparin	unfractionated heparin		Exploratory	Negative
Thery, 1992	Nadroparin	unfractionated heparin		Exploratory	Negative
reviparin
COLOMBUS sub group, 1997	Reviparin	unfractionated heparin		Exploratory	Negative
rivaroxaban
Einstein-PE Evaluation, 2012	rivaroxaban (without LMWH)	LMWH/VKA		Risk of bias	-	NCT00439777
tinzaparin
ACTSG (Hull) sub-group, 1992	Tinzaparin	unfractionated heparin		Exploratory	Negative
THESEE, 1997	Tinzaparin	unfractionated heparin		Risk of bias	Negative
Campbell, 1998	Tinzaparin	unfractionated heparin			Negative
stable angina
aspirin
SAPAT, 1992	aspirin	placebo		Low risk of bias	Suggesting
clopidogrel
ASCET	clopidogrel	aspirin		Risk of bias	Negative	NCT00222261
dipyridamol
Foulds, 1960	dipyridamol	placebo		Exploratory	-
Zion, 1961	dipyridamol	placebo		Exploratory	-
Dewar, 1961	dipyridamol	placebo		Exploratory	-
Kinsella, 1962	dipyridamol	placebo		Exploratory	-
Leiberman, 1964	dipyridamol	placebo		Exploratory	-
Neumann, 1964	dipyridamol	placebo		Exploratory	-
Atlanta (Sbar), 1967	dipyridamol	control		Exploratory	Negative
Becker, 1967	dipyridamol	control		Exploratory	Negative
Wirecki, 1967	dipyridamol	control		Exploratory	Negative
Igloe, 1970	dipyridamol	placebo		Exploratory	-
ticlopidine
Berglund, 1985	ticlopidine	placebo		Exploratory	Negative
stent
cilostazol
Kunishima, 1997	cilostazol	aspirin			Negative
Sekiya, 1998	cilostazol + aspirin	aspirin			Negative
Ochiai, 1999	cilostazol + aspirin	ticlopidine + aspirin			Negative
Park, 1999	cilostazol + aspirin	ticlopidine + aspirin			Negative
Yoon, 1999	cilostazol + aspirin	ticlopidine + aspirin			Negative
Kozuma, 2001	cilostazol + aspirin	ticlopidine + aspirin			Negative
Kamishirado, 2002	cilostazol + aspirin	ticlopidine + aspirin			Negative
clopidogrel
Müller, 2000	clopidogrel + aspirin	ticlopidine + aspirin			Negative
CLASSICS, 2000	clopidogrel + aspirin	ticlopidine + aspirin			Negative
TOPPS, 2001	clopidogrel + aspirin	ticlopidine + aspirin			Negative
Piamsomboon, 2001	clopidogrel + aspirin	ticlopidine + aspirin			Negative
REAL-LATE, ZEST-LATE, 2010	clopidogrel+aspirin	aspirin			Negative	NCT00484926
GRAVITAS, 2011	high-dose clopidogrel	normal-dose clopidogrel		Risk of bias	Negative	NCT00645918
ticlopidine
ISAR, 1996	ticlopidine + aspirin	coumadin + aspirin			Suggesting
Hall, 1996	ticlopidine + aspirin	aspirin			Negative
FANTASTIC, 1998	ticlopidine + aspirin	coumadin + aspirin			Negative
MATTIS, 1998	ticlopidine + aspirin	coumadin + aspirin			Negative
STARS (vs coumadin+asp), 1998	ticlopidine + aspirin	coumadin + aspirin			Suggesting
STARS (vs aspirin), 1998	ticlopidine + aspirin	aspirin			Suggesting
Foussas, 2000	ticlopidine + aspirin	coumadin + aspirin			Suggesting
superficial thrombophlebitis
candesartan
Andreozzi (200 vs 100), 1996	desmin 200	desmin 100			-
Andreozzi (desmin SC vs 100), 1996	desmin SC	desmin 100			-
coumadin
Belcaro (coumadin vs low dose hep), 1999	coumadin	low dose heparin			-
defibrotide
Belcaro, 1990	defibrotide	low dose heparin			-
Diclofenac
Nocker (diclofenac), 1991	Diclofenac	placebo			-
enoxaparin
Stenox (enoxaparin 40mg), 2003	enoxaparin	placebo			-
STENOX (enoxaparin 1.5mg/hg), 2003	enoxaparin	placebo			-
fondaparinux
CALISTO, 2010	fondaparinux	placebo		Low risk of bias	Suggesting	NCT00443053
heparin
Belcaro (hep vs no hep), 1989	heparin	no treatment			-
Belcaro (hep vs defibrotide), 1990	heparin				-
Marchiori, 2002	heparin	low dose UFH			-
Katzenschlager, 2003	liposomal heparin-spraygel	enoxaparin			-
Gorski, 2005	heparin spraygel	clexane			-
nadroparin
Titon (nadroparin 0.6ml vs naproxen), 1994	nadroparin	naproxene			-
Titon (nadroparin 61.5 IU anti-Xa/kg vs naproxen), 1994	nadroparin	naproxene			-
Vesalio, 2005	nadroparin fixed-dose	nadroparin weight-adjusted			-
Nimesulide
Ferrari, 1992	Nimesulide	diclofenac			-
UFH
Belcaro (prophylactic UFH vs no), 1999	Prophylactic UFH	no treatment			-
thrombosis prevention
acenocoumarol
van Geloven, 1977	Acenocoumarol	unfractionated heparin			-
Hamulyak, 1994	Acenocoumarol	Nadroparin			Negative
Samama, 2001	Acenocoumarol	Reviparin			Negative
apixaban
APROPOS 2.5mg, 2007	apixaban	enoxaparin (US regimen)	knee surgery	Exploratory	Negative	NCT00097357
ADVANCE 3, 2010	apixaban	enoxaparin	hip surgery	Low risk of bias	Suggesting	NCT00423319
ADVANCE 2, 2010	apixaban	enoxaparin (europe regimen)	knee surgery	Low risk of bias	Suggesting	NCT00452530
ADOPT, 2011	apixaban	enoxaparin	medical patients	Low risk of bias	Suggesting	NCT00457002
CV185-027 ongoing	apixaban	placebo			-	NCT00320255
ardeparin
Godwin, 1993	ardeparin	unfractionated heparin	abdominal surgery		-
Levine, 1996	ardeparin	placebo	knee surgery		Suggesting
Heit, 2000	out of hospital Ardeparin	standard prophylaxis			Negative
aspirin
MRC, 1972	aspirin	placebo		Low risk of bias	Negative
Zekert-I , 1974	Aspirin	placebo		Exploratory	Suggesting
Loew DVT, 1974	aspirin	placebo		Low risk of bias	-
Stockholm-I, 1975	Aspirin	placebo		Exploratory	Negative
Clagett, 1975	aspirin	control		Risk of bias	-
Powers , 1976	Aspirin	placebo		Exploratory	Suggesting
Pasteyer, 1977	Aspirin	no treatment		Exploratory	Negative
Harris-I, 1977	Aspirin	placebo		Low risk of bias	Suggesting
Vinazzer II, 1977	aspirin	placebo		Low risk of bias	-
Erfurt-B , 1979	Aspirin	placebo		Exploratory	Negative
Erfurt-A, 1979	aspirin	placebo		Low risk of bias	-
McKenna-I, 1980	Aspirin	placebo		Exploratory	Suggesting
Zekert V, 1980	aspirin	placebo		Low risk of bias	-
Vinazzer I, 1980	aspirin	placebo		Low risk of bias	-
Zekert VI, 1982	aspirin	control		Risk of bias	-
Sautter, 1983	Aspirin	placebo		Exploratory	Suggesting
McBride, 1983	Aspirin	placebo		Exploratory	Negative
Rocha, 1986	Aspirin	no treatment		Exploratory	Suggesting
PEP hip-fracture, 2000	aspirin	placebo		Low risk of bias	Suggesting
PEP elective arthroplasty, 2000	aspirin	placebo		Low risk of bias	-
betrixaban
APEX, 2016	betrixaban	enoxaparin	medical patients	Low risk of bias	Suggesting	NCT01583218
candesartan
Eriksson, 1996	desirudin	UFH			-
Ericksson, 1997	desirudin	enoxaparin			-
REVASC, 1997	desirudin	UFH			-
Certoparin
Schmitz-Huebner, 1984	certoparin	unfractionated heparin	abdominal surgery		Negative
Sasahara, 1986	certoparin	unfractionated heparin	abdominal surgery		Suggesting
Voigt, 1986	certoparin	unfractionated heparin	abdominal surgery		Negative
Haas , 1987	certoparine + DHE	Unfractionated heparin	hip surgery		Negative
Lassen, 1988	certoparine + DHE	Unfractionated heparin	hip surgery		Suggesting
Welzel, 1988	certoparin	unfractionated heparin	abdominal surgery		Suggesting
Lassen, 1989	certoparine + DHE	Unfractionated heparin	hip surgery		Negative
Kakkar, 1989	certoparin	unfractionated heparin	abdominal surgery		Negative
Adolf, 1989	certoparin	unfractionated heparin	abdominal surgery		Negative
Heilmann, 1989	certoparin	unfractionated heparin	gynaecological surgery		Negative
Baumgartner, 1989	certoparin	unfractionated heparin	abdominal surgery		Negative
Hoffmann and Largiade, 1990	certoparin	unfractionated heparin	abdominal surgery		Negative
Koppenhagen, 1990	certoparin	unfractionated heparin	abdominal surgery		-
Schielke, 1991	certoparin	unfractionated heparin	abdominal surgery		-
Koppenhagen, 1992	certoparin	unfractionated heparin	abdominal surgery		-
Hoffmann and Largiader, 1992	certoparin	unfractionated heparin	abdominal surgery		-
Kock, 1995	certoparin	control		Risk of bias	Negative
Heilmann, 1997	certoparin	unfractionated heparin	gynaecological surgery		-
Haas, 1999	certoparin	unfractionated heparin	general surgery		-
CERTIFY, 2010	certoparin	UFH	medical patients		-
dabigatran
RE-NOVATE 2	dabigatran 220mg	enoxaparin	hip surgery	Low risk of bias	Negative	NCT00657150
RE-MODEL (220mg), 2007	dabigatran 220mg	enoxaparin (europe regimen)	knee surgery	Low risk of bias	Negative
RE-NOVATE (220mg), 2007	dabigatran 220mg	enoxaparin	hip surgery	Low risk of bias	Negative	NCT00168818
RE-MODEL (150mg), 2007	dabigatran 150mg	enoxaparin (europe regimen)	knee surgery	Low risk of bias	Negative
RE-NOVATE (150mg), 2007	dabigatran 150mg	enoxaparin	hip surgery	Low risk of bias	Negative	NCT00168818
RE-MOBILIZE (220mg), 2008	dabigatran 220mg	enoxaparin (US regimen)	knee surgery	Low risk of bias	Negative
RE-MOBILIZE (150mg), 2008	dabigatran 150mg	enoxaparin (US regimen)	knee surgery	Low risk of bias	Negative
dalteparin
Haas , 1985	dalteparin	Unfractionated heparin	hip surgery		Negative
Binsack , 1986	dalteparin	Unfractionated heparin	hip surgery		Negative
Bergqvist, 1986	dalteparin	unfractionated heparin	abdominal surgery		Negative
Onarheim, 1986	dalteparin	unfractionated heparin	abdominal surgery		Negative
Koller, 1986	dalteparin	unfractionated heparin	abdominal surgery		Negative
Koller, 1986	dalteparin	unfractionated heparin	abdominal surgery		Negative
Barre , 1987	dalteparin	Unfractionated heparin	hip surgery		Negative
Eriksson , 1988	dalteparin	Dextran	hip surgery		Suggesting
Matzsch , 1988	dalteparin	Dextran	hip surgery		Negative
Fricker, 1988	dalteparin	unfractionated heparin	abdominal surgery		Negative
Bergqvist, 1988	dalteparin	unfractionated heparin	abdominal surgery		Negative
Caen, 1988	dalteparin	unfractionated heparin	abdominal surgery		Negative
Borstad, 1988	dalteparin	unfractionated heparin	gynaecological surgery		Negative
Briel, 1988	dalteparin	unfractionated heparin	non orthopedic surgery		Negative
Jorgensen, 1989	dalteparin	placebo	hip surgery		Suggesting
Dechavanne , 1989	dalteparin	Unfractionated heparin	hip surgery		Negative
Eriksson , 1989	dalteparin	Unfractionated heparin	hip surgery		Suggesting
Monreal , 1989	dalteparin	Unfractionated heparin	hip surgery		Negative
Ockelford , 1989	dalteparin	placebo			Suggesting
Creperio, 1990	dalteparin	unfractionated heparin	general surgery		Negative
Hartl, 1990	dalteparin	unfractionated heparin	abdominal surgery		Suggesting
Scala, 1990	dalteparin	UFH		Risk of bias	Negative
Torholm, 1991	dalteparin	placebo	hip surgery		Suggesting
Matzsch , 1991	dalteparin	Dextran	hip surgery		Suggesting
Borstad, 1992	dalteparin	unfractionated heparin	gynaecological surgery		-
Kakkar, 1993	dalteparin	unfractionated heparin	abdominal surgery		-
Dahl, 1997	out of hospital Dalteparin	standard prophylaxis			Suggesting
Lassen, 1998	out of hospital Dalteparin	standard prophylaxis			Negative
Hull, 2000	out of hospital Dalteparin	standard prophylaxis			Suggesting
Leizorovicz, 2004	dalteparin	placebo	medical patients		Suggesting
Lapidus, 2007	dalteparin	placebo		Low risk of bias	Negative
Lapidus, 2007	dalteparin	placebo		Low risk of bias	Negative
D-KAf (Selby), 2007	dalteparin	placebo			Negative	NCT00187408
PROTECT, 2011	dalteparin	UFH	medical patients	Low risk of bias	Suggesting	NCT00182143
deltaparin
Michot, 2002	deltaparin	control		Risk of bias	Suggesting
dipyridamol
Parodi I, 1973	dipyridamol + aspirin	control		Exploratory	Suggesting
Parodi II, 1973	dipyridamol + aspirin	control		Risk of bias	-
Lyon-I, 1975	aspirin + dipyridamol	no treatment		Exploratory	Suggesting
Australian I, 1975	dipyridamol + aspirin	control		Risk of bias	-
Hamburg, 1976	aspirin + dipyridamol	placebo		Exploratory	Negative
Encke-II , 1976	aspirin + dipyridamol	placebo		Exploratory	Negative
Australian II, 1976	dipyridamol + aspirin	control		Risk of bias	-
Encke IA, 1976	dipyridamol + aspirin	placebo		Exploratory	-
Encke IB, 1976	dipyridamol + aspirin	placebo		Exploratory	-
Morris-A , 1977	dipyridamol	no treatment		Exploratory	Negative
Morris-B , 1977	aspirin + dipyridamol	no treatment		Exploratory	Negative
Zekert-III, 1977	dipyridamol + aspirin	control		Risk of bias	-
Weiss, 1977	dipyridamol + aspirin	control		Exploratory	-
Toulouse I, 1979	dipyridamol + aspirin	control		Risk of bias	-
Frankfurt, 1981	aspirin + dipyridamol	placebo		Exploratory	Negative
Chicago, 1982	aspirin + dipyridamol	control		Exploratory	Negative
Harjola DVT, 1982	dipyridamol + aspirin	control		Risk of bias	-
edoxaban
STARS J-V	edoxaban	enoxaparin (short duration)	hip surgery	Low risk of bias	Suggesting	NCT01181167
DU176b-B-J302 ongoing	edoxaban	enoxaparin	knee surgery		-	NCT01181102
DU176b-B-J303 ongoing	edoxaban	enoxaparin	hip surgery		-	NCT01181141
DU176b-B-J304 ongoing	edoxaban	enoxaparin	hip surgery		-	NCT01181167
DU176b-04 ongoing	edoxaban	placebo	knee surgery		-	NCT01203072
enoxaparin
Ho [43]	enoxaparin	no treatment			Negative
Turpie, 1986	enoxaparin	placebo	hip surgery		Suggesting
LeGagneux , 1987	enoxaparin	placebo			Negative
Melon, 1987	enoxaparin	placebo			Negative
Planes , 1988	enoxaparin	Unfractionated heparin	hip surgery		Suggesting
Samama 1, 1988	enoxaparin	unfractionated heparin	general surgery		Negative
Samama 2, 1988	enoxaparin	unfractionated heparin	general surgery		Negative
Samama 3, 1988	enoxaparin	unfractionated heparin	general surgery		Negative
Leclerc, 1991	enoxaparin	placebo	knee surgery		Suggesting
DES Group , 1991	enoxaparin	Dextran	hip surgery		Suggesting
Levine , 1991	enoxaparin	Unfractionated heparin	hip surgery		Negative
Kaaja, 1992	enoxaparin	unfractionated heparin	gynaecological surgery		-
Gazzaniga (ISG), 1993	enoxaparin	unfractionated heparin	general surgery		-
Warwick, 1995	enoxaparin	no treatment	hip surgery		Negative
Nurmohamed, 1995	enoxaparin	unfractionated heparin	general surgery		-
McLeod (Canadian), 1995	enoxaparin	unfractionated heparin	abdominal surgery		-
Kalodiki, 1996	enoxaparin	placebo	hip surgery		-
Bergqvist, 1996	out of hospital Enoxaparin	standard prophylaxis			Suggesting
Planes, 1996	out of hospital Enoxaparin	standard prophylaxis			Negative
Bergmann and Neuhart, 1996	enoxaparin	UFH	medical patients		Negative
Lechler, 1996	enoxaparin	UFH	medical patients		Negative
Gonzalez, 1996	enoxaparin	unfractionated heparin	abdominal surgery		-
Samama, 1997	enoxaparin	placebo	hip surgery		Suggesting
ENOXACAN, 1997	enoxaparin	unfractionated heparin	abdominal surgery		-
Agnelli, 1998	enoxaparin	placebo			Suggesting
MEDENOX, 1999	Enoxaparin	placebo	medical patients	Low risk of bias	Suggesting
Comp, 2001	out of hospital Enoxaparin	standard prophylaxis			Suggesting
Kleber, 2003	enoxaparin	UFH	medical patients		Negative
Canata, 2003	enoxaparin	control		Exploratory	Negative
Lederle, 2006	Enoxaparin	placebo	medical patients		Negative
LIFENOX, 2011	enoxaparin	placebo	medical patients	Low risk of bias	Negative	NCT00622648
fondaparinux
BRiEF	fondaparinux	enoxaparin	medical patients		-	NCT00521885
L8541	fondaparinux	enoxaparin	orthopaedic surgery	Low risk of bias	Negative
L8635	fondaparinux	enoxaparin	knee surgery	Exploratory	Negative
DRI4757	fondaparinux	placebo	knee surgery	Exploratory	-
PENTAMAKS (Bauer), 2001	fondaparinux	enoxaparin	knee surgery	Low risk of bias	Suggesting
PENTHIFRA (Eriksson), 2001	fondaparinux	enoxaparin	hip surgery	Low risk of bias	Suggesting
Turpie, 2001	fondaparinux	enoxaparin	hip surgery	Exploratory	-
PENTATHLON (Turpie), 2002	fondaparinux	enoxaparin	hip surgery	Low risk of bias	Suggesting
EPHESUS (Lassen), 2002	fondaparinux	enoxaparin	hip surgery		Suggesting
PEGASUS, 2005	fondaparinux	enoxaparin	abdominal surgery	Low risk of bias	Negative
ARTEMIS (Cohen), 2006	fondaparinux	placebo	medical patients		Negative
APOLLO (Turpie), 2007	fondaparinux	placebo (on top intermittent pneumatic comp.)	abdominal surgery	Low risk of bias	Suggesting
NCT00333021 ongoing	fondaparinux	control			-	NCT00333021
PROTECT (fundaparinux) ongoing	fondaparinux	no treatment			-	NCT00881088
FONDACAST ongoing	fondaparinux	nadroparin			-	NCT00843492
NCT00320398 ongoing	fondaparinux	control			-	NCT00320398
fraxiparin
Pezzuoli, 1989	nadroparin	placebo			Suggesting
Leyvraz, 1991	nadroparin	Unfractionated heparin	hip surgery		Negative
Roth, 1995	nadroparin	control			Negative
LMWH
Harenberg, 1990	LMWH	UFH	medical patients		Negative
Harenberg, 1996	LMWH	UFH	medical patients		Negative
nadroparin
Balas [40]	nadroparin	placebo			Negative
Marassi [41]	nadroparin	no treatment			Negative
Kakkar and Murray, 1985	nadroparin	unfractionated heparin	general surgery		Suggesting
EFS, 1988	nadroparin	unfractionated heparin	abdominal surgery		Suggesting
Dahan, 1989	nadroparin	unfractionated heparin	thoracic surgery		Negative
Barbui, 1990	nadroparin	unfractionated heparin	general surgery		-
Kujath, 1993	nadroparin	control		Risk of bias	Suggesting
Eurin, 1994	nadroparin	unfractionated heparin	abdominal surgery		-
Sourmelis, 1995	nadroparin	placebo	hip surgery		Suggesting
Bergmann, 1996	nadroparin	placebo	medical patients		Negative
Nurmohamed, 1996	nadroparin	placebo			Negative
Yoo, 1997	nadroparin	no treatment	hip surgery		Negative
NPHDO, 1998	out of hospital Nadroparin	standard prophylaxis			Negative
Fraisse, 2000	Nadroparin	placebo	medical patients		Negative
Mahe, 2005	Nadroparin	placebo	medical patients		Negative
KANT (7 days), 2008	nadroparin	control		Risk of bias	Suggesting
KANT (14 days), 2008	nadroparin 14d	control		Risk of bias	Suggesting
PROTECT (nadroparin) ongoing	nadroparin	no treatment			-	NCT00881088
phenindione
Eskeland, 1966	Phenindione	no treatment			-
Hamilton, 1970	Phenindione	no treatment			-
reviparin
Kakkar, 1993	reviparin	unfractionated heparin	general surgery		-
Wirth, 2001	reviparin	control		Low risk of bias	Negative
Lassen, 2002	reviparin	placebo		Low risk of bias	Suggesting
rivaroxaban
ODIXa-KNEE, 2005	rivaroxaban	enoxaparin (US regimen)	knee surgery	Exploratory	Negative
ODIXa-HIP 10mg, 2006	rivaroxaban	enoxaparin (short duration)	hip surgery	Exploratory	Suggesting
RECORD 1, 2008	rivaroxaban	enoxaparin	hip surgery	Low risk of bias	Suggesting	NCT00329628
RECORD 2, 2008	rivaroxaban (long duration)	enoxaparin (short duration)	hip surgery	Low risk of bias	Suggesting	NCT00332020
RECORD 3, 2008	rivaroxaban	enoxaparin (europe regimen)	knee surgery	Low risk of bias	Suggesting	NCT00361894
RECORD 4, 2009	rivaroxaban	enoxaparin (US regimen)	knee surgery	Low risk of bias	Suggesting	NCT00362232
MARINER, 2018	rivaroxaban	placebo	medical patients		Suggesting	NCT02111564
suloctidil
Turpie, 1985	Suloctidil	placebo		Low risk of bias	-
ticlopidine
Walker, 1974	ticlopidine	placebo		Exploratory	-
Lasierra, 1982	ticlopidine	placebo		Exploratory	-
McKenna-II, 1983	Ticlopidine	placebo		Exploratory	Negative
McKenna-II , 1983	ticlopidine	placebo			Negative
Lyon-II	Ticlopidine	placebo		Exploratory	Negative
Gardecki	Ticlopidine	placebo		Exploratory	Negative
tinzaparin
Bergqvist [42]	tinzaparin	placebo			Negative
Lassen, 1991	tinzaparin	placebo	hip surgery		Suggesting
Leizorovicz, 1991	tinzaparin	unfractionated heparin	abdominal surgery		-
Jorgensen, 2002	tinzaparin	control		Risk of bias	Negative
UFH
Cade	UFH	control	medical patients		-
Kakkar (IMT)	UFH	no treatment			-
Gruber	UFH	no treatment			-
Torngren	UFH	placebo			-
Kakkar, 1972	UFH	placebo			-
Gordon-Smith, 1972	UFH	no treatment			-
Nicolaides, 1972	UFH	no treatment			-
Handley (low dose), 1972	UFH	control		Risk of bias	Negative
Handley, 1972	UFH	control		Risk of bias	Negative
Gallus , 1973	UFH	no treatment			Suggesting
Gallus, 1973	UFH	no treatment			-
Gallus, 1973	UFH	control		Risk of bias	Negative
Emerson, 1973	UFH	control		Risk of bias	Suggesting
Warlow, 1973	UFH	control		Low risk of bias	Suggesting
Morris, 1974	UFH	no treatment			Suggesting
Hampson, 1974	UFH	placebo			Negative
Dechavanne, 1974	UFH	no treatment			Suggesting
Multiunit, 1974	UFH	no treatment			-
Abernethy, 1974	UFH	no treatment			-
Sagar, 1974	UFH	no treatment			-
Kettunen, 1974	UFH	no treatment			-
Abraham-Inpijn , 1975	UFH	placebo			Negative
VTCSG, 1975	UFH	no treatment			Negative
Dechavanne, 1975	UFH	no treatment			Suggesting
Lahnborg, 1975	UFH	placebo			-
Covey, 1975	UFH	placebo			-
Strand, 1975	UFH	placebo			-
Roberts, 1975	UFH	placebo			-
Ribaudo, 1975	UFH	placebo			-
Sebeseri, 1975	UFH	no treatment			-
Mannucci , 1976	UFH	no treatment			Suggesting
Galasko , 1976	UFH	no treatment			Suggesting
Lahnborg, 1976	UFH	placebo			-
Gallus, 1976	UFH	no treatment			-
Kraytman, 1976	UFH	no treatment			-
Xabregas , 1977	UFH	placebo			Negative
Morris , 1977	UFH	no treatment			Negative
Wu, 1977	UFH	placebo			-
Lawrence, 1977	UFH	placebo			-
van Geloven, 1977	UFH	oral anticoagulant			-
Loew, 1977	UFH	aspirin			-
Kraytman, 1977	UFH	placebo			-
Kraytman, 1977	UFH	no treatment			-
Kutnowski, 1977	UFH	placebo			-
Williams , 1978	UFH	placebo			Negative
Moskovitz, 1978	UFH	placebo			Suggesting
Moskovitz, 1978	UFH	placebo			Negative
Kiil, 1978	UFH	placebo			-
Torngren, 1978	UFH	placebo			-
Taberner, 1978	UFH	placebo			-
Torngren, 1978	UFH	placebo			-
Coe, 1978	UFH	no treatment			-
Allen, 1978	UFH	no treatment			-
Cerrato, 1978	UFH	no treatment			Suggesting
Bergqvist , 1979	UFH	no treatment			Suggesting
Bergqvist, 1979	UFH	no treatment			Suggesting
Plante, 1979	UFH	no treatment			-
Abraham-Inpijn, 1979	UFH	no treatment			-
Groote Schuur, 1979	UFH	no treatment			-
Ziemski, 1979	UFH	no treatment			-
Hedlund, 1979	UFH	placebo			-
Lahnborg, 1980	UFH	placebo			Suggesting
Belch, 1980	UFH	placebo			-
Vinazzer, 1980	UFH	aspirin			-
Bergqvist, 1980	UFH	no treatment			-
Kruse-Blinkenberg, 1980	UFH	placebo			-
Vandendris, 1980	UFH	placebo			-
Pitt, 1980	UFH	placebo		Risk of bias	Negative
Lowe , 1981	UFH	placebo			Suggesting
Svend-Hansen, 1981	UFH	placebo			Suggesting
Blech, 1981	UFH	control	medical patients		Suggesting
Spebar, 1981	UFH	no treatment			-
Welin-Berger, 1982	UFH	no treatment			Negative
Koppenhagen, 1982	UFH	no treatment			-
Marchetti, 1982	UFH	placebo			-
Clarke-Pearson, 1983	UFH	no treatment			-
Marchelli, 1983	UFH	no treatment			-
Bejjani, 1983	UFH	placebo			-
Muiticentre, 1984	UFH	placebo			-
Muiticentre 53,S4, 1984	UFH	DHE			-
Muiticentre, 1984	UFH	DHE			-
Jourdan, 1984	UFH	placebo			-
Caloghera, 1984	UFH	no treatment			-
Zawilska, 1989	UFH	control		Risk of bias	Suggesting
Gardlund, 1996	UFH	control	medical patients		Suggesting
Manganelli, 1998	out of hospital UFH	standard prophylaxis			Negative
warfarin
Myrhe, 1969	Warfarin	placebo			-
Myrhe, 1969	Warfarin	Dextran			-
Pinto, 1970	Warfarin	no treatment			-
Harris, 1972	Warfarin	Dextran			-
Hume, 1973	Warfarin	no treatment			-
Hume, 1973	Warfarin	Sudoxicam			-
Hume, 1973	Warfarin	unfractionated heparin			-
Morris, 1976	Warfarin	no treatment			-
Barber, 1977	Warfarin	Dextran			-
Barber, 1977	Warfarin	unfractionated heparin			-
Francis, 1983	Warfarin	Dextran			-
Paiement, 1987	Warfarin	Intermittent pneumatic compression			-
Powers, 1989	Warfarin	no treatment			-
Powers, 1989	Warfarin	Aspirin			-
Bailey, 1991	Warfarin	Intermittent pneumatic compression			-
Kaempffe, 1991	Warfarin	Intermittent pneumatic compression			-
Gerhart, 1991	Warfarin	Danaparoid			-
Francis, 1992	Warfarin	Intermittent pneumatic compression			-
Hull, 1993	Warfarin	Logiparin			Suggesting
RD Heparin, 1994	Warfarin	Ardeparin			Suggesting
Leclerc, 1996	Warfarin	Enoxaparin			Suggesting
Francis, 1997	Warfarin	Dalteparin			Suggesting
Heit, 1997	Warfarin	Ardeparin			Suggesting
Lotke, 1997	Warfarin	Aspirin			-
van Comp, 1998	Warfarin	Danaparoid			-
Colwell, 1999	Warfarin	Enoxaparin			Suggesting
Hull, 2000	Warfarin	Dalteparin			Suggesting
Fitzgerald, 2001	Warfarin	Enoxaparin			Suggesting
ximelagatran
Phase II (Heit), 2001	ximelagatran	Enoxaparin			Negative
METHRO I, 2002	ximelagatran	Dalteparin			Negative
METHRO II, 2002	ximelagatran	Dalteparin			Suggesting
METHRO III, 2002	ximelagatran	Enoxaparin			Negative
Platinum (Colwell), 2003	ximelagatran	Enoxaparin			Negative
EXPRESS, 2003	ximelagatran	Enoxaparin			Suggesting
venous thrombosis
apixaban
Botticelli DVT, 2008	apixaban (without LMWH)	LMWH/VKA		Exploratory	-	NCT00252005
AMPLIFY-EXT 2.5mg, 2012	apixaban 2.5mg	discontinuation			Suggesting	NCT00633893
AMPLIFY-EXT 5mg, 2012	apixaban 5mg	discontinuation			Suggesting	NCT00633893
AMPLIFY, 2013	apixaban (without LMWH)	LMWH/VKA		Low risk of bias	Suggesting	NCT00643201
CAP ongoing	apixaban				-	NCT02581176
CARAVAGGIO ongoing	apixaban	dalteparin			-	NCT03045406
aspirin
WARFASA, 2012	aspirin	discontinuation			Suggesting	NCT00222677
ASPIRE, 2012	aspirin	discontinuation			Suggesting	ACTRN12605000004662
Bemiparin
Kakkar, 2003	Bemiparin	warfarin		Risk of bias	Negative
dabigatran
RE-COVER, 2009	heparin/dabigatran	heparin/VKA		Low risk of bias	Suggesting	NCT00291330
RE-MEDY, 2011	dabigatran	warfarin		Low risk of bias	Suggesting	NCT00329238
RE-SONATE, 2011	dabigatran	discontinuation			Suggesting	NCT00558259
dalteparin
Bratt et al , 1985	Dalteparin	unfractionated heparin			Negative
Holm et al , 1986	Dalteparin	unfractionated heparin			Negative
Bratt et al, 1990	Dalteparin	unfractionated heparin			Negative
Holmström, 1992	once daily dalteparin	twice daily dalteparin			Negative
Lindmarker et al , 1993	Dalteparin	unfractionated heparin			Negative
Partsch, 1996	once daily dalteparin	twice daily dalteparin			Negative
Das, 1996	Dalteparin	warfarin		Risk of bias	Negative
Lee, 2003	Dalteparin	warfarin		Risk of bias	Suggesting
CLOT (Lee), 2003	extended dalteparin	standard treatment			Suggesting
edoxaban
Hokusai-VTE Cancer, 2017	edoxaban	dalteparin	patients with cancer		Negative	NCT02073682
enoxaparin
Simonneau et al , 1993	Enoxaparin	unfractionated heparin			Negative
Pini, 1994	Enoxaparin	warfarin		Risk of bias	Negative
Gonzalez-Fajardo, 1999	Enoxaparin	warfarin		Risk of bias	Suggesting
Veiga, 2000	Enoxaparin	acenocoumarol		Risk of bias	Negative
Merli, 2001	once daily enoxaparin	twice daily enoxaparin			Negative
Merli (once daily vs UFH), 2001	once daily enoxaparin	UFH		Low risk of bias	Negative
Meyer, 2002	Enoxaparin	warfarin		Risk of bias	Negative
Meyer, 2002	extended enoxaparin	standard treatment			Negative
Deitcher, 2003	Enoxaparin	warfarin		Risk of bias	Negative
Cesarone, 2003	extended enoxaparin	standard treatment			Negative
Deitcher, 2006	extended enoxaparin	standard treatment			Negative
González-Fajardo, 2008	Enoxaparin	coumarin		Risk of bias	-
fondaparinux
MATISSE PE, 2003	fondaparinux	heparin		Risk of bias	Negative
MATISSE, 2004	fondaparinux	enoxaparin		Low risk of bias	Negative
heparin
Krahenbuhl, 1979	subcutaneous heparin	intravenous heparin			-
Bentley, 1980	subcutaneous heparin	intravenous heparin			Suggesting
Andersson, 1982	subcutaneous heparin	intravenous heparin			-
Hull, 1986	subcutaneous heparin	intravenous heparin			Negative
Doyle, 1987	subcutaneous heparin	intravenous heparin			Negative
Walker, 1987	subcutaneous heparin	intravenous heparin			Suggesting
Pini, 1990	subcutaneous heparin	intravenous heparin			Negative
Nielsen importé, 1994	heparin+phenprocoumon	phenylbutazone			-
Ott importé, 1998	heparin+warfarin	placebo			Negative
Lopaciuk	subcutaneous heparin	intravenous heparin			Negative
idraparinux
VanGogh DVT, 2007	idraparinux (without heparin)	heparin/VKA		Exploratory	Suggesting	NCT00067093
VanGogh PE, 2007	idraparinux (without heparin)	heparin/VKA		Risk of bias	Negative	NCT00062803
Van Gogh (subgroup), 2011	idraparinux	standard treatment	patients with cancer	Exploratory	Negative
logiparin
Siegbahn, 1989	once daily logiparin	twice daily logiparin			Negative
nadroparin
Collaborative European Multicentre, 1991	Nadroparin	unfractionated heparin			Negative
Prandoni et al , 1992	Nadroparin	unfractionated heparin			Suggesting
Lopaciuk et al , 1992	Nadroparin	unfractionated heparin			Negative
Charbonnier, 1998	once daily nadroparin	twice daily nadroparin			Negative
Lopaciuk, 1999	Nadroparin	acenocoumarol		Risk of bias	Negative
Lopez-Beret, 2001	Nadroparin	acenocoumarol		Risk of bias	Negative
Lopez Beret, 2001	extended nadroparin	standard treatment			Negative
rivaroxaban
Einstein-DVT Dose-Ranging Study, 2008	rivaroxaban (without LMWH)	LMWH/VKA			-
EINSTEIN-extension, 2009	rivaroxaban	discontinuation		Low risk of bias	Suggesting	NCT00439725
Einstein-DVT Evaluation, 2010	rivaroxaban (without LMWH)	LMWH/VKA		Low risk of bias	Suggesting	NCT00440193
Einstein-PE Evaluation, 2012	rivaroxaban (without LMWH)	LMWH/VKA		Risk of bias	-	NCT00439777
EINSTEIN (subgroup), 2014	rivaroxaban	enoxaparin	patients with cancer		Suggesting
SELECT D, 2018	rivaroxaban	dalteparin	patients with cancer		Suggesting
CONKO-011 ongoing	rivaroxaban				-	NCT02583191
CASTA-DIVA ongoing	rivaroxaban				-	NCT02746185
rosuvastatin
VanGogh extension, 2007	idraparinux	discontinuation			Suggesting	NCT00071279
tinzaparin
Hull et al , 1992	Tinzaparin	unfractionated heparin			Suggesting
Hull, 2002	Tinzaparin	warfarin		Risk of bias	Negative
Hull, 2006	extended tinzaparin	standard treatment			Negative
Romera, 2009	Tinzaparin	acenocoumarol		Risk of bias	Suggesting
warfarin
Levine, 1995	warfarin	discontinuation			Suggesting
Schulman, 1995	6 months	1.5 months			Suggesting
DURAC (Schulman), 1997	warfarin	discontinuation			Suggesting
LAFIT (Kearon), 1999	warfarin	discontinuation			Suggesting
Agnelli, 2001	warfarin	discontinuation			Negative
Pinede, 2001	3-6 months	1.5-3 months			Negative
Agnelli, 2003	warfarin	discontinuation			Negative
PREVENT (Ridker), 2003	warfarin	discontinuation			Suggesting
ELAET (Kearon), 2004	warfarin	discontinuation			Negative
Wells (subgroup), 2005	tinzaparin	dalteparin			Negative
PROLONG (Palareti), 2006	warfarin	discontinuation			Suggesting	NCT00264277
ximelagatran
THRIVE III, 2003	ximelagatran	discontinuation		Low risk of bias	Suggesting
THRIVE I, 2003	ximelagatran (without LMWH)	LMWH/VKA			-
Schulman (subgroup), 2003	ximelagatran	placebo	patients with cancer		-
Fiessinger , 2005	ximelagatran	LMWH/VKA			-

antithrombotics Trials Results

Group by...

acute coronary syndrome

apixaban

argatroban

aspirin

atopaxar

bivalirudin

clopidogrel

coumadin

dalteparin

dipyridamol

Efegatran

enoxaparin

fondaparinux

hirudin

inogatran

nadroparin

otamixaban

prasugrel

rivaroxaban

sulfinpyrazone

ticagrelor

ticlopidine

trapidil

triflusal

UFH

vorapaxar

warfarin

ximelagatran

acute myocardial infarction

argatroban

bivalirudin

coumadin

dalteparin

enoxaparin

fondaparinux

hirudin

reviparin

UFH

warfarin

atrial fibrillation

apixaban

aspirin

clopidogrel

coumadin

dabigatran

edoxaban

idraparinux

rivaroxaban

triflusal

warfarin

ximelagatran

heart failure

aspirin

clopidogrel

enoxaparin

rivaroxaban

warfarin

percutaneous coronary intervention

abciximab

aspirin

bivalirudin

cangrelor

cilostazol

clopidogrel

dalteparin

dipyridamol

elinogrel

enoxaparin

eptifibatide

fondaparinux

prasugrel

reviparin

sulotroban

ticlopidine

tirofiban

peripheral vascular diseases

acenocoumarol

aspirin

antithrombotics
Trials Results